Expo Live Innovation Impact grant recipient oDocs Eye Care is striving to improve access to preventive treatment
The Expo Live Innovation Impact Grant Programme (IIGP) was established to elevate social enterprises, non-profits and startups that are aligned to environmental or humanitarian causes.
One of the recipients of the grant is New Zealand-based oDocs Eye Care, a company that specialises in building open-source, affordable diagnostic imaging equipment.
The company’s goal is to end preventable blindness, according to its founders Hong Sheng Chiong and Benjamin O’Keeffe, a pair of doctors who have developed smartphone-enabled eye-care solutions.
The doctors have created a functional fundus camera that attaches to a smartphone and allows a doctor to look at the back of a patient’s eye to make basic diagnoses.
Share
Hugh Green overcame hardship to become a leading New Zealand businessman. Now, his philanthropic legacy is supporting world-leading research aimed to help newborn babies to breathe.
Theo is “thriving” after his mum took part in the C STEROID Trial. Photo credit: Hannah Webb Photography.
Associate Professor Katie Groom and her team at the University of Auckland’s Liggins Institute believe a simple treatment will safely prevent short-term breathing problems that are more common in babies born by planned or elective caesarean section than in other newborns.
Hugo Charitable Trust donations over the past four years allowed Dr Groom to lay the groundwork for a nationwide research trial funded by the Health Research Council of New Zealand.
Thursday, 18 February 2021, 10:27 am
Hugh Green overcame hardship to become a leading
New Zealand businessman. Now, his philanthropic legacy is
supporting world-leading research aimed to help newborn
babies to breathe.
Associate Professor Katie
Groom and her team at the University of Auckland’s Liggins
Institute believe a simple treatment will safely prevent
short-term breathing problems that are more common in babies
born by planned or elective caesarean section than in other
newborns.
Hugo Charitable Trust donations over the
past four years allowed Dr Groom to lay the groundwork for a
nationwide research trial funded by the Health Research
Council of New Zealand.
(File photo)
Article continues below advertisement ↴
An international trial tested in over 300 hospitals around the world have concluded that blood thinners improve the outcome for hospitalized COVID-19 patients.
The University of Manitoba released the conclusion of the trials in a media release on Friday.
The introduction of full-dose blood thinners for patients who had mild symptoms of the virus showed a reduced need for organ support.
The release says that three clinical trial platforms spanning five continents in over 300 hospitals have been working together since May 2020 to urgently test whether there is a greater benefit of full doses of heparin (blood thinners) to treat adults hospitalized for non-critical COVID-19 illness compared to the lower dose typically administered to prevent blood clots in hospitalized patients.